Document is current
Any future updates will be listed below
-
Authors
Schweitzer, Paula K. https://orcid.org/0000-0001-6081-1620
Maynard, James P.
Wylie, Paul E. https://orcid.org/0000-0002-1563-5872
Emsellem, Helene A.
Sands, Scott A. https://orcid.org/0000-0003-3752-0328
-
Funding
Funding for this research was provided by:
Apnimed Inc.
- License Information
-
More Information
Article History
Received: 2 February 2022
Revised: 25 March 2022
Accepted: 2 May 2022
First Online: 13 May 2022
Declarations
:
: The study was approved by institutional review boards at each site and performed in accordance with the Declaration of Helsinki; all participants provided written informed consent ( identifier NCT04445688, 24JUN2020).
: P Schweitzer has received consultancy fees from Apnimed, Inc. and Jazz Pharmaceuticals; her institution has received research funding from Apnimed, Inc., Avadel, Inspire Medical Systems, Jazz Pharmaceuticals, and Suven Life Sciences.J Maynard reports no conflicts.P Wylie reports no conflicts.H. Emsellem has received research funding from Apnimed, Inc., Jazz Pharmaceuticals, Avadel, NLS, Philips, Suven, Vanda Pharmaceuticals, and Takeda. She has participated in advisory boards for Avadel, Harmony Biosciences, and Takeda.S Sands has received consulting fees from Apnimed, Nox Medical, Merck, and Inspire, and received grant support from Apnimed, Prosomnus, and Dynaflex.
